View ValuationCell Impact 将来の成長Future 基準チェック /06現在、 Cell Impactの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長25.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.すべての更新を表示Recent updatesお知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15, by hantverket on sturegatan 15, stockholm Swedenお知らせ • Feb 04+ 4 more updatesCell Impact AB (publ) to Report Q1, 2026 Results on May 13, 2026Cell Impact AB (publ) announced that they will report Q1, 2026 results at 9:00 AM, Central European Standard Time on May 13, 2026Reported Earnings • Aug 24Second quarter 2025 earnings released: kr0.03 loss per share (vs kr0.035 loss in 2Q 2024)Second quarter 2025 results: kr0.03 loss per share. Net loss: kr21.2m (loss widened 1.7% from 2Q 2024).お知らせ • May 20Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million.Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 3,133,220,076 Price\Range: SEK 0.02 Transaction Features: Rights Offeringお知らせ • Apr 24Cell Impact AB (Publ) Announces Board ChangesCell Impact AB (publ) at the annual general meeting held on 24 April 2025 Mats Boquist was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15 konferens, & event on sturegatan 15, stockholm Swedenお知らせ • Feb 14+ 4 more updatesCell Impact AB (publ) to Report Q2, 2025 Results on Aug 22, 2025Cell Impact AB (publ) announced that they will report Q2, 2025 results on Aug 22, 2025Board Change • Dec 30No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Nov 06+ 1 more updateCell Impact AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cell Impact AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025お知らせ • Sep 10Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024The Board of Directors has appointed Daniel Vallin as the permanent CEO of Cell Impact. Daniel Vallin has been serving as interim CEO since January 1, 2024. Daniel Vallin, with extensive industrial experience from companies such as Scania CV AB, was recruited to Cell Impact as COO in 2021 and has been the interim CEO of Cell Impact since the beginning of 2024. Today, the board of directors of Cell Impact has appointed him as the permanent CEO with effect from October 1, 2024.Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr24.0m (up 37% from 2Q 2023). Net loss: kr20.9m (loss narrowed 27% from 2Q 2023).お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.お知らせ • Jul 03Cell Impact Adds Sealing as A New Part of Production ProcessCell Impact AB (publ) continues to develop its production process to better meet customer demand. The latest addition to the company’s production process is the opportunity to seal bipolar flow plates through dispersion. Sealing is a critical part of the assembly of bipolar flow plates for fuel cells and electrolyzers. Dispensing is one of the most popular sealing solutions used in the industry today.Reported Earnings • May 15First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)First quarter 2024 results: kr0.04 loss per share (improved from kr0.40 loss in 1Q 2023). Revenue: kr6.10m (down 70% from 1Q 2023). Net loss: kr23.4m (loss narrowed 23% from 1Q 2023).お知らせ • Apr 26Cell Impact AB (Publ) Announces Board and Committee ChangesCell Impact AB (publ) announced that at the AGM held on 25 April 2024, elected Jan Pieters and Mats Boquist as board members for the period until the end of the next annual general meeting. Mats Franzén was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.Reported Earnings • Feb 18Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)Full year 2023 results: kr1.11 loss per share. Revenue: kr47.7m (down 48% from FY 2022). Net loss: kr121.4m (loss widened 17% from FY 2022).New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.05m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (96% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Market cap is less than US$10m (€9.05m market cap, or US$9.82m).お知らせ • Jan 18+ 1 more updateCell Impact AB (Publ) Appoints Henrik Jackman as Chief Application EngineerCell Impact AB (publ) announced appointment of Henrik Jackman as Chief Application Engineer. The company's management already includes Daniel Vallin, CEO, Karina Sick Larsson, CHRO and Stefan Axellie, CFO (Malin Lundberg from February 12).Recent Insider Transactions • Dec 29Chief Executive Officer recently bought €4.5k worth of stockOn the 20th of December, Pär Teike bought around 238k shares on-market at roughly €0.019 per share. This transaction increased Pär's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of €19k worth in shares.お知らせ • Dec 20Cell Impact AB (publ) Announces CEO ChangesCell Impact AB (publ) announced that Pär Teike, CEO since 2017, has decided to leave his role and Cell Impact. Daniel Vallin, Cell Impact's COO since 2021, is proposed to take over as acting CEO from January 1, 2024, until a decision is made regarding a permanent CEO of Cell Impact. Daniel Vallin, 46 years old, is a Master of Science in Industrial Engineering with extensive industrial experience from among others, Scania CV AB.New Risk • Dec 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (88% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.3m market cap, or US$15.7m).お知らせ • Dec 13Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFOCell Impact AB (publ) announced that Stefan Axellie, has decided to leave his role and Cell Impact by spring 2024. The process of identifying a successor will start within short. Stefan Axellie will stay on in his role until spring 2024 during the recruitment of his successor.Reported Earnings • Nov 04Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (improved from kr0.38 loss in 3Q 2022). Revenue: kr9.19m (down 38% from 3Q 2022). Net loss: kr24.9m (loss narrowed 14% from 3Q 2022).お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.06m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr163m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€9.06m market cap, or US$9.54m).お知らせ • Sep 29Cell Impact AB (publ) Announces Anna Frick Will Leave the BoardCell Impact AB (publ) is announcing that board member Anna Frick will leave the board at her own request.お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.お知らせ • Jul 04Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product DevelopmentCell Impact AB (publ) announced that it is created by forming very thin sheets of metal with high velocity, in a single stroke, to create complex patterns. Extreme precision is required for the finished flow plate to work. With this new measuring technology, there is unique capacity to measure up to one-twentieth of a single strand of hair. To secure the best possible conditions, the measuring facility is built as a separate entity within the factory in Karlskoga. The slightest vibrations affect the measurement result - as do changes in temperature. Therefore, there is no contact between the room and external walls and the temperature is kept at 20 degrees around the clock, with a permissible variation of 0.4 degrees. The measuring equipment is used to measure flow plates, forming tools and fixtures. The investment in new measurement technology is part of Phase II, Cell Impact's strategy to develop its offering and productivity, which aims to better satisfy the customers' development objectives. The instruments include Hexagon Global Blue 7.10.7, Hexagon Global Blue 12.22.10 and Leitz PMM Gold 7.7.5, and gives Cell Impact better opportunities to measure complex geometries quickly, accurately, and continuously.お知らせ • Feb 18+ 6 more updatesCell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024Cell Impact AB (publ) announced that they will report fiscal year 2023 results on Mar 24, 2024Reported Earnings • Feb 18Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)Full year 2022 results: kr1.38 loss per share (further deteriorated from kr1.35 loss in FY 2021). Revenue: kr92.1m (up 13% from FY 2021). Net loss: kr104.2m (loss widened 31% from FY 2021).Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Nov 05Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)Third quarter 2022 results: kr0.38 loss per share (further deteriorated from kr0.25 loss in 3Q 2021). Revenue: kr14.7m (down 47% from 3Q 2021). Net loss: kr28.9m (loss widened 97% from 3Q 2021).Reported Earnings • Aug 26Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr26.5m (up 27% from 2Q 2021). Net loss: kr22.2m (loss narrowed 6.6% from 2Q 2021).お知らせ • May 26Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTCCell Impact AB (publ) PUBL SHARE AK B (Sweden) will be deleted from Other OTC effective from May 26, 2022, due to CUSIP Suspended.Board Change • May 13High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cell Impact は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:ICL - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20266-129-46-44N/A12/31/20256-132-47-45N/A9/30/20257-104-53-49N/A6/30/202512-99-34-29N/A3/31/202534-99-45-36N/A12/31/202438-100-77-62N/A9/30/202437-100-106-81N/A6/30/202440-107-146-108N/A3/31/202434-114-159-113N/A12/31/202348-121-159-106N/A9/30/202365-113-164-114N/A6/30/202373-117-163-109N/A3/31/202377-111-188-125N/A12/31/202278-104-174-106N/A9/30/202281-102-178-103N/A6/30/202291-88-173-102N/A3/31/202291-89-149-88N/A12/31/202182-80-140-86N/A9/30/202170-66-126-77N/A6/30/202151-57-101-60N/A3/31/202135-47-77-43N/A12/31/202029-44-70-48N/A9/30/202022-49-50-36N/A6/30/202017-52-58-47N/A3/31/202017-50-57-44N/A12/31/201912-48N/A-41N/A9/30/201912-44N/A-43N/A6/30/201911-47N/A-40N/A3/31/20198-48N/A-45N/A12/31/20187-45N/A-43N/A9/30/20184-40N/A-35N/A6/30/20181-33N/A-28N/A3/31/20181-23N/A-21N/A12/31/20172-18N/A-16N/A9/30/20173-14N/A-13N/A6/30/20173-11N/A-10N/A3/31/20173-8N/A-9N/A12/31/20162-9N/A-9N/A9/30/20162-7N/A-7N/A6/30/20162-7N/A-7N/A3/31/20161-8N/A-6N/A12/31/20152-7N/A-6N/A9/30/20152-8N/A-6N/A6/30/20153-8N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ICLの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ICLの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ICLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ICLの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ICLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ICLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 21:41終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cell Impact AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Mats HyttingeCarlsquare AB
お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.
お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.
お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.
お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15, by hantverket on sturegatan 15, stockholm Sweden
お知らせ • Feb 04+ 4 more updatesCell Impact AB (publ) to Report Q1, 2026 Results on May 13, 2026Cell Impact AB (publ) announced that they will report Q1, 2026 results at 9:00 AM, Central European Standard Time on May 13, 2026
Reported Earnings • Aug 24Second quarter 2025 earnings released: kr0.03 loss per share (vs kr0.035 loss in 2Q 2024)Second quarter 2025 results: kr0.03 loss per share. Net loss: kr21.2m (loss widened 1.7% from 2Q 2024).
お知らせ • May 20Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million.Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 3,133,220,076 Price\Range: SEK 0.02 Transaction Features: Rights Offering
お知らせ • Apr 24Cell Impact AB (Publ) Announces Board ChangesCell Impact AB (publ) at the annual general meeting held on 24 April 2025 Mats Boquist was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.
お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15 konferens, & event on sturegatan 15, stockholm Sweden
お知らせ • Feb 14+ 4 more updatesCell Impact AB (publ) to Report Q2, 2025 Results on Aug 22, 2025Cell Impact AB (publ) announced that they will report Q2, 2025 results on Aug 22, 2025
Board Change • Dec 30No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Nov 06+ 1 more updateCell Impact AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cell Impact AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
お知らせ • Sep 10Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024The Board of Directors has appointed Daniel Vallin as the permanent CEO of Cell Impact. Daniel Vallin has been serving as interim CEO since January 1, 2024. Daniel Vallin, with extensive industrial experience from companies such as Scania CV AB, was recruited to Cell Impact as COO in 2021 and has been the interim CEO of Cell Impact since the beginning of 2024. Today, the board of directors of Cell Impact has appointed him as the permanent CEO with effect from October 1, 2024.
Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr24.0m (up 37% from 2Q 2023). Net loss: kr20.9m (loss narrowed 27% from 2Q 2023).
お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.
お知らせ • Jul 03Cell Impact Adds Sealing as A New Part of Production ProcessCell Impact AB (publ) continues to develop its production process to better meet customer demand. The latest addition to the company’s production process is the opportunity to seal bipolar flow plates through dispersion. Sealing is a critical part of the assembly of bipolar flow plates for fuel cells and electrolyzers. Dispensing is one of the most popular sealing solutions used in the industry today.
Reported Earnings • May 15First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)First quarter 2024 results: kr0.04 loss per share (improved from kr0.40 loss in 1Q 2023). Revenue: kr6.10m (down 70% from 1Q 2023). Net loss: kr23.4m (loss narrowed 23% from 1Q 2023).
お知らせ • Apr 26Cell Impact AB (Publ) Announces Board and Committee ChangesCell Impact AB (publ) announced that at the AGM held on 25 April 2024, elected Jan Pieters and Mats Boquist as board members for the period until the end of the next annual general meeting. Mats Franzén was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.
Reported Earnings • Feb 18Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)Full year 2023 results: kr1.11 loss per share. Revenue: kr47.7m (down 48% from FY 2022). Net loss: kr121.4m (loss widened 17% from FY 2022).
New Risk • Jan 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.05m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (96% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Market cap is less than US$10m (€9.05m market cap, or US$9.82m).
お知らせ • Jan 18+ 1 more updateCell Impact AB (Publ) Appoints Henrik Jackman as Chief Application EngineerCell Impact AB (publ) announced appointment of Henrik Jackman as Chief Application Engineer. The company's management already includes Daniel Vallin, CEO, Karina Sick Larsson, CHRO and Stefan Axellie, CFO (Malin Lundberg from February 12).
Recent Insider Transactions • Dec 29Chief Executive Officer recently bought €4.5k worth of stockOn the 20th of December, Pär Teike bought around 238k shares on-market at roughly €0.019 per share. This transaction increased Pär's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of €19k worth in shares.
お知らせ • Dec 20Cell Impact AB (publ) Announces CEO ChangesCell Impact AB (publ) announced that Pär Teike, CEO since 2017, has decided to leave his role and Cell Impact. Daniel Vallin, Cell Impact's COO since 2021, is proposed to take over as acting CEO from January 1, 2024, until a decision is made regarding a permanent CEO of Cell Impact. Daniel Vallin, 46 years old, is a Master of Science in Industrial Engineering with extensive industrial experience from among others, Scania CV AB.
New Risk • Dec 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (88% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€14.3m market cap, or US$15.7m).
お知らせ • Dec 13Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFOCell Impact AB (publ) announced that Stefan Axellie, has decided to leave his role and Cell Impact by spring 2024. The process of identifying a successor will start within short. Stefan Axellie will stay on in his role until spring 2024 during the recruitment of his successor.
Reported Earnings • Nov 04Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (improved from kr0.38 loss in 3Q 2022). Revenue: kr9.19m (down 38% from 3Q 2022). Net loss: kr24.9m (loss narrowed 14% from 3Q 2022).
お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.
New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.06m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr163m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€9.06m market cap, or US$9.54m).
お知らせ • Sep 29Cell Impact AB (publ) Announces Anna Frick Will Leave the BoardCell Impact AB (publ) is announcing that board member Anna Frick will leave the board at her own request.
お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.
お知らせ • Jul 04Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product DevelopmentCell Impact AB (publ) announced that it is created by forming very thin sheets of metal with high velocity, in a single stroke, to create complex patterns. Extreme precision is required for the finished flow plate to work. With this new measuring technology, there is unique capacity to measure up to one-twentieth of a single strand of hair. To secure the best possible conditions, the measuring facility is built as a separate entity within the factory in Karlskoga. The slightest vibrations affect the measurement result - as do changes in temperature. Therefore, there is no contact between the room and external walls and the temperature is kept at 20 degrees around the clock, with a permissible variation of 0.4 degrees. The measuring equipment is used to measure flow plates, forming tools and fixtures. The investment in new measurement technology is part of Phase II, Cell Impact's strategy to develop its offering and productivity, which aims to better satisfy the customers' development objectives. The instruments include Hexagon Global Blue 7.10.7, Hexagon Global Blue 12.22.10 and Leitz PMM Gold 7.7.5, and gives Cell Impact better opportunities to measure complex geometries quickly, accurately, and continuously.
お知らせ • Feb 18+ 6 more updatesCell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024Cell Impact AB (publ) announced that they will report fiscal year 2023 results on Mar 24, 2024
Reported Earnings • Feb 18Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)Full year 2022 results: kr1.38 loss per share (further deteriorated from kr1.35 loss in FY 2021). Revenue: kr92.1m (up 13% from FY 2021). Net loss: kr104.2m (loss widened 31% from FY 2021).
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Nov 05Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)Third quarter 2022 results: kr0.38 loss per share (further deteriorated from kr0.25 loss in 3Q 2021). Revenue: kr14.7m (down 47% from 3Q 2021). Net loss: kr28.9m (loss widened 97% from 3Q 2021).
Reported Earnings • Aug 26Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr26.5m (up 27% from 2Q 2021). Net loss: kr22.2m (loss narrowed 6.6% from 2Q 2021).
お知らせ • May 26Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTCCell Impact AB (publ) PUBL SHARE AK B (Sweden) will be deleted from Other OTC effective from May 26, 2022, due to CUSIP Suspended.
Board Change • May 13High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.